Sumitomo Mitsui Trust Group Inc. Purchases 38,833 Shares of Moderna, Inc. $MRNA

Sumitomo Mitsui Trust Group Inc. increased its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 187.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 59,590 shares of the company’s stock after purchasing an additional 38,833 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Moderna were worth $11,475,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Western Pacific Wealth Management LP purchased a new position in shares of Moderna during the 3rd quarter worth approximately $29,000. Allied Private Wealth LLC acquired a new stake in shares of Moderna in the 2nd quarter valued at approximately $30,000. Archer Investment Corp purchased a new stake in shares of Moderna in the second quarter valued at approximately $36,000. Ramsey Quantitative Systems purchased a new stake in shares of Moderna in the third quarter valued at approximately $40,000. Finally, Assetmark Inc. grew its holdings in Moderna by 35.1% during the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after acquiring an additional 208 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In other news, insider Shannon Klinger sold 3,471 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider directly owned 74,129 shares in the company, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James M. Mock sold 34,836 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 197,251 shares of company stock worth $33,875,904. 10.80% of the stock is owned by corporate insiders.

Moderna Price Performance

MRNA traded up $12.73 during trading on Friday, reaching $254.19. 16,295,043 shares of the stock were exchanged, compared to its average volume of 18,981,452. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The company has a market capitalization of $101.48 billion, a price-to-earnings ratio of -31.81 and a beta of 1.16. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $267.50. The business’s 50 day moving average price is $191.85 and its two-hundred day moving average price is $91.51.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $1.48. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $890.25 million. During the same quarter in the previous year, the company posted ($0.51) EPS. The business’s revenue was up 29.2% on a year-over-year basis. As a group, equities research analysts anticipate that Moderna, Inc. will post -6.11 earnings per share for the current year.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported third-quarter revenue of $1.31 billion, up 29.2% year over year, and earnings of $0.38 per share, far ahead of analysts’ expectations for a loss. Stronger overseas COVID-19 vaccine sales helped drive the results. Reuters report on revenue and demand
• Positive Sentiment: Management raised its 2026 revenue-growth forecast to 15%–25%, from a prior outlook of up to 10%. The company also said it plans to reduce research and development spending, supporting its near-term financial performance. CNBC outlook report
• Positive Sentiment: Health Canada authorized Moderna’s seasonal flu and flu-COVID combination vaccines for adults 50 and older, opening a potential new market for its mRNA products. CBC report on Canadian approvals
• Positive Sentiment: Investors are also watching prospects for Moderna’s cancer vaccine: CEO Stéphane Bancel said it could have potential beyond melanoma. That adds pipeline excitement, though future commercial value remains uncertain. Yahoo Finance report on cancer vaccine prospects
• Neutral Sentiment: Moderna and GSK settled a patent dispute involving Moderna’s COVID and RSV shots. The settlement removes a source of legal uncertainty, but the available report does not specify its financial terms. Reuters report on patent settlement
• Negative Sentiment: The sharp rally has heightened concerns that expectations for the cancer-vaccine pipeline may be running ahead of near-term revenue potential. Moderna’s longer-term prospects still depend on sustaining vaccine sales and turning pipeline advances into commercial products. Barron’s analysis of Moderna’s earnings and valuation

Analyst Ratings Changes

MRNA has been the subject of a number of recent analyst reports. The Goldman Sachs Group raised their target price on Moderna from $120.00 to $137.00 and gave the company a “neutral” rating in a report on Thursday, October 15th. Barclays increased their price target on shares of Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a report on Monday, August 24th. Singular Research raised shares of Moderna to a “hold” rating in a report on Wednesday, September 23rd. Evercore upped their target price on shares of Moderna from $50.00 to $80.00 in a research report on Thursday, October 8th. Finally, Morgan Stanley increased their target price on shares of Moderna from $89.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Six research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and an average price target of $107.10.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.

The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.

Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.